Forget Canopy Growth: This Little-Known Cannabis Stock Is Insanely Profitable

Here’s one undiscovered cannabis gem that could outperform Canopy Growth stock over the next 12 months.

| More on:
edit Jars of marijuana

Image source: Getty Images

For a good number of years, Canopy Growth (TSX:WEED)(NASDAQ:CGC) has been the go-to cannabis stock for investors who needed a piece of the nascent industry’s pie. The Canadian marijuana giant enjoyed first-mover advantages in the product market and on stock market indexes. However, cannabis investors looking for outperforming returns have to look elsewhere right now.

It’s true that WEED still has one of the strongest balance sheets among TSX-listed marijuana stocks. The company retains over $2.3 billion in cash and short-term investments after Constellation Brands’s $5 billion injection in 2018 and a US$750 million debt raise in March. However, if phenomenal growth is what you are looking for, there’s one small, little-known, and seemingly undervalued cannabis stock you could buy over Canopy Growth stock today.

Canopy Growth has struggled to deliver

For all the $10 billion company’s efforts since 2016, Canopy Growth has grown its annual revenue run rate to nearly $547 million. But the company has generated more operating losses than what it booked as revenue in each of the past four years. The company’s historical financial performance has been horrible.

Canopy Growth 5 year revenue and operating earnings 2016-2021
Canopy Growth in steady annual revenue growth, and worse operating losses. (Figures in CAD Millions). (Source: TIKR Terminal.)

Just recently, the company reported $148.4 million in quarterly revenue during the first three months of this calendar year. Sales generated a mere 14% in adjusted gross margins, and the company printed a $616.7 million net loss. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) loss of $94 million was more than half of quarterly revenue, and $466 million cash was “burnt” in operations in three months.

In contrast, one recently listed TSX marijuana firm reported stellar results during the same period. It could deliver even better numbers later this year.

This tiny TSX marijuana stock is poised to outperform

InterCure (TSX:INCR.U) is an Israeli cannabis firm that was recently listed on the TSX through a merger with a special purpose acquisition company (SPAC). The company’s subsidiary, Canndoc, is the leading marijuana player in Israel. It reports in New Israeli Shekels (NIS).

InterCure grew its quarterly revenue eight-fold in 12 months to NIS 33 million (CAD 12.2 million) by March 31, 2021. The company reported a strong 45% adjusted gross margin, and management forecasts the stellar growth trajectory to persist throughout this year.

Most noteworthy, InterCure reported a positive adjusted EBITDA of C$3.5 million (a 30% margin) and generated positive cash flow from operations of C$3.7 million from pot operations. This marked a third consecutive quarter of positive operating cash flow which was driven by revenue growth and profitability improvements.

I like the small company’s revenue and operating earnings trend.

InterCure Ltd. in strong sequential revenue growth and profitability
InterCure in strong sequential revenue and profitability growth. (Figures in NIS Millions). (Source:TIKR Terminal.)

The smaller player is evidently fairing better than its larger peer, and its story is only unfolding.

Massive growth ahead

InterCure reported an eight-fold revenue increase while it had only two operational medical marijuana pharmacies during the first quarter of 2021. Subsequent acquisitions will increase the pharmacy chain to 12 locations across the country during the year. The company’s local market has been reportedly growing at rates around 4% a month.

On one hand, analysts expect InterCure to grow its revenue by 148% over the next twelve months. New product launches, higher productive capacity, a broader market reach, and strong support from international suppliers could make this a reality. The company is generating profits and cash flows while importing significant flower supplies from Canada and Uruguay.

On the other hand, Canopy Growth could grow revenue by 41% over the next 12 months. There’s a slight hope it can turn adjusted EBITDA positive in 2022. The company has struggled to contain operating expenses after it aggressively grew its global footprint beyond market capacity over the years.

Foolish bottom line

New investors in Canopy Growth stock are paying 14 times the company’s expected next twelve months (NTM) sales per share. Yet the company continues to lose money.

On the other hand, InterCure stock is priced at just 3.1 times NTM revenue. The company is already profitable and could grow 3.6 times faster than CGC while generating positive operating cash flows.

Canopy Growth has arguably maintained its steep valuation due to wider market publicity. However, InterCure stock is a bargain buy right now. Cathie Wood’s ARK Invest is already a major shareholder.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »